• DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival 

      Pedersen, Christine Aaserød; Cao, Maria Dung; Fleischer, Thomas; Rye, Morten Beck; Knappskog, Stian; Eikesdal, Hans Petter; Lønning, Per Eystein; Tost, Jörg; Kristensen, Vessela N.; Tessem, May-Britt; Giskeødegård, Guro F.; Bathen, Tone Frost (Peer reviewed; Journal article, 2022)
      Background Locally advanced breast cancer is a heterogeneous disease with respect to response to neoadjuvant chemotherapy (NACT) and survival. It is currently not possible to accurately predict who will benefit from the ...
    • Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer 

      Yndestad, Synnøve; Engebrethsen, Christina; Herencia-Ropero, A.; Nikolaienko, Oleksii; Vintermyr, Olav Karsten; Lillestøl, Reidun Kristine; Minsaas, Laura; Leirvaag, Beryl; Iversen, Gjertrud Titlestad; Gilje, Bjørnar; Blix, Egil Støre; Espelid, Helge; Lundgren, Steinar; Geisler, Jürgen; Aase, Hildegunn Siv; Aas, Turid; Gudlaugsson, Einar; Llop-Guevara, Alba; Serra, Violeta; Janssen, Emiel; Lønning, Per Eystein; Knappskog, Stian; Eikesdal, Hans Petter (Peer reviewed; Journal article, 2023)
      Purpose Homologous recombination deficiency (HRD) is highly prevalent in triple-negative breast cancer (TNBC) and associated with response to PARP inhibition (PARPi). Here, we studied the prevalence of HRD in non-TNBC to ...
    • Olaparib monotherapy as primary treatment in unselected triple negative breast cancer 

      Eikesdal, Hans Petter; Yndestad, Synnøve; Elzawahry, Asmaa; Llop-Guevara, Alba; Gilje, Bjørnar; Blix, Egil Støre; Espelid, Helge; Lundgren, Steinar; Geisler, Jürgen; Vagstad, Geirfinn; Venizelos, Andreas; Minsaas, Laura; Leirvaag, Beryl; Gudlaugsson, Einar; Vintermyr, Olav Karsten; Aase, Hildegunn Siv; Aas, Turid; Balmaña, Judith; Serra, Violeta; Janssen, Emiel; Knappskog, Stian; Lønning, Per Eystein (Peer reviewed; Journal article, 2020)
      Background The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi monotherapy was ineffective in patients with metastatic ...
    • Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development 

      Nikolaienko, Oleksii; Eikesdal, Hans Petter; Berge, Elisabet Ognedal; Gilje, Bjørnar; Lundgren, Steinar; Blix, Egil Støre; Espelid, Helge; Geisler, Jürgen; Geisler, Stephanie; Janssen, Emiel; Yndestad, Synnøve; Minsaas, Laura; Leirvaag, Beryl; Lillestøl, Reidun Kristine; Knappskog, Stian; Lønning, Per Eystein (Peer reviewed; Journal article, 2023)
      Background Normal cell BRCA1 epimutations have been associated with increased risk of triple-negative breast cancer (TNBC). However, the fraction of TNBCs that may have BRCA1 epimutations as their underlying cause is ...
    • Semi-automatic segmentation from intrinsically-registered 18F-FDG-PET/MRI for treatment response assessment in a breast cancer cohort: comparison to manual DCE-MRI 

      Andreassen, Maren Marie Sjaastad; Goa, Pål Erik; Sjøbakk, Torill Eidhammer; Hedayati, Roja; Eikesdal, Hans Petter; Deng, Callie; Østlie, Agnes; Lundgren, Steinar; Bathen, Tone Frost; Jerome, Neil Peter (Journal article; Peer reviewed, 2019)
      Objectives To investigate the reliability of simultaneous positron emission tomography and magnetic resonance imaging (PET/MRI)-derived biomarkers using semi-automated Gaussian mixture model (GMM) segmentation on PET ...